Michael Kleven, DO
Family Medicine · Surprise, AZNPI 1447323423
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,374 and has fallen 59.8% since, to $552 in 2023.
Across 223 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$511
- AstraZeneca$351
- Novo Nordisk$349
- Amgen$278
- Abbott$239
- Idorsia Pharmaceuticals US Inc$195
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,946100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,961 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 121 | $155,501 |
| EliquisApixaban | 174 | $93,127 |
| FarxigaDapagliflozin Propanediol | 95 | $88,356 |
| OzempicSemaglutide | 63 | $87,075 |
| JardianceEmpagliflozin | 73 | $64,487 |
| TrulicityDulaglutide | 27 | $43,441 |
| Repatha SureclickEvolocumab | 50 | $37,755 |
| XareltoRivaroxaban | 62 | $34,046 |
| JanuviaSitagliptin Phosphate | 19 | $28,147 |
| Repatha SyringeEvolocumab | 18 | $24,353 |
| ZenpepLipase/Protease/Amylase | 16 | $21,158 |
| MyrbetriqMirabegron | 19 | $15,297 |
| CreonLipase/Protease/Amylase | 11 | $14,869 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,018 |
| VascepaIcosapent Ethyl | 14 | $7,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $121 | $198,942148 claims |
| PfizerEliquis | $32 | $93,127174 claims |
| AstraZenecaFarxiga | $351 | $88,35695 claims |
| Novo NordiskOzempic | $349 | $87,07563 claims |
| Boehringer IngelheimJardiance | $60 | $64,48773 claims |
| Johnson & JohnsonXarelto | $63 | $34,04662 claims |
| MerckJanuvia | $104 | $28,14719 claims |
| AbbVieCreon, Synthroid | $511 | $17,96243 claims |
| Astellas Pharma US IncMyrbetriq | $168 | $15,29719 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $72 | $13,91338 claims |
| Sanofi-aventis U.S. LLCLantus | $191 | $5,50624 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $15 | $5,16527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Surprise
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
- Suzanne BentzMesa$174K
- Brent AllanParadise Valley$108K
- Ahmed AghaPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.